Starlix

Known as: Novartis brand of nateglinide 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1999-2009
01219992009

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2009
Review
2009
We present a case of an 82-year-old African American male who presented to the ED with rapaglinide-induced hypoglycemia who was… (More)
Is this relevant?
2005
2005
 
  • table 1
Is this relevant?
2004
2004
The objective of the study was to determine the effect of a potent and selective CYP2C9 inhibitor, sulfinpyrazone (Anturane), on… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Review
2003
Review
2003
Nateglinide is a new oral antidiabetic agent that stimulates insulin release promptly after its pre-meal administration in a… (More)
Is this relevant?
2003
2003
  • 2003
Nateglinide is an amino-acid derivative that lowers blood glucose levels by stimulating insulin secretion from the pancreas. This… (More)
  • table 1
  • table 2
Is this relevant?
Review
2003
Review
2003
  • Drug and therapeutics bulletin
  • 2003
[symbol: see text] Nateglinide (Starlix-Novartis) and [symbol: see text] repaglinide (NovoNorm-Novo Nordisk) are two of a new… (More)
Is this relevant?
2002
2002
Several factors have to be taken into account for successful therapeutic patient education: patients' acceptance of the illness… (More)
Is this relevant?
1999
1999
Nateglinide (Starlix, SDZ DJN 608 or A-4166), a new insulinotropic agent, is intended to be administered prior to a meal in order… (More)
Is this relevant?